PATENT CLAIM ANALYSIS

Application Number: 15925013
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "468000"]

Abstract:
Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.

Claim (Index 47):
The method of  claim 46 , the tablet comprising an amount of 1-{[\u03b1-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid ranging from 300 mg to 700 mg.

Metadata:
- Claim Count in Document: 95.0
- Percentile: 90.0
- Lexical Diversity: 1.17949
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14309662', '11269045', '15359321', '13164620', '14206893']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.758741274397039
- 35 USC 102 Novelty (BERT): 0.6300416342869751
- Combined Prediction Score: 0.7458713103860326
- Mean Citation Score: 496.648788
- Max Citation Score: 623.77496
- Similarity Product: 522.8585278843259

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test